Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes.

Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices giant had some weakness in recent years amid disappointing trends from its ...

Shares of Medtronic (NYSE: MDT ... And in the highly competitive diabetes care segment, the new MiniMed 780G insulin pump system employs AI algorithms to predict and automatically adjust insulin ...

Growth potential rests heavily on the diabetes segment, where the MiniMed 780G ... think that Medtronic is positioned to dominate. As always, there are also questions of cost (insulin pens are ...